10 GLP-1 drug commercialization experts

Experience: VP Oral Semaglutide Diabetes Marketing · Novo Nordisk

Former VP Oral Semaglutide Diabetes Marketing at Novo Nordisk (2022–2024), and VP CVD Marketing & Launch there since October 2024. Annika earlier held Global Commercial Associate Director Oral Semaglutide Diabetes (2020–2021), Global Commercial Associate Director Portfolio Strategy (2021–2022) and Global Commercial Director CVD, Ziltivekimab (2022) roles at Novo Nordisk.

Experience: Global Marketing Vice President Diabetes GLP-1 & incretin pipeline · Novo Nordisk

Global Marketing Vice President Diabetes GLP-1 & incretin pipeline at Novo Nordisk (2025–2026), and AVP Cardiometabolic Brand Strategy & Marketing there since January 2026. Fahad earlier held Vice President Global Marketing Once-Weekly Insulin Portfolio (2024–2025) and Global commercial director (2022–2024) roles at Novo Nordisk; the profile cites 14+ years of pharmaceutical experience, including lifecycle management.

Experience: Director, Obesity BU(Wegovy Launched on 15th Oct 2024 & Saxenda) · Novo Nordisk

Director, Obesity BU at Novo Nordisk Korea since March 2023, covering Wegovy (launched on 15 October 2024, per the title) and Saxenda; the profile describes leading an obesity business unit with more than 90 sales FTE across 10 teams. Other roles include Asso.Director, Oncology at AstraZeneca (2019–2023), Sr. Marketing Manager, IO(Opdivo) Liver Cancer & New Product Planning, Hepatitis C Marketing Lead at Bristol Myers Squibb (2016–2019) and Toujeo Launch Leader of Insulin Team, Cardiovascular Marketing(PCSK9i, Praluent) at Sanofi (2015–2016).

Experience: Global Brand Director - Mounjaro · Eli Lilly and Company

Global Brand Director - Mounjaro at Eli Lilly and Company (2019–2022), Senior Director, Global Marketing - Mounjaro (2022–2023) and Executive Director, Obesity Global Marketing (2023–2024). Jian's profile describes being part of the team creating the Mounjaro, Zepbound and Trulicity brands and shaping Lilly's diabetes and obesity pipeline assets; Jian has been a freelance Pharma Biotech Strategy Advisor since 2025.

Experience: Project Vice President, Semaglutide Projects · Novo Nordisk

Project Vice President, Semaglutide Projects at Novo Nordisk since November 2022, where the profile describes leading lifecycle management for Wegovy. Kathrine was previously Vice President, Obesity Strategy & Pipeline Projects (2021–2022) and Senior Global Director, Obesity Market Development (2018–2021) at Novo Nordisk, and the headline cites global launch and lifecycle leadership across the semaglutide portfolio.

Experience: Senior Global Director, Strategic Marketing, Obesity · Novo Nordisk

Former Senior Global Director, Strategic Marketing, Obesity at Novo Nordisk (2025–2026), a role the profile describes as leading global digital strategy and consumer marketing for the launch of Wegovy Pill, including direct-to-patient ecosystems and partnerships. Lasse was earlier Senior Global Director, Consumer Experience & Innovation, Obesity at Novo Nordisk (2023–2025) and Global Future Lab Director at Designit (2018–2023).

Experience: Global Commercial Lead GLP-1, Obesity · Sandoz

Global Commercial Lead GLP-1, Obesity at Sandoz since May 2026. At Novo Nordisk, Miriam was Marketing Manager GLP-1 at Novo Nordisk Pharma GmbH (2018–2020), Business Unit Director Obesity (2022–2024), Business Unit Director Diabetes and Obesity (2024–2025) and Medical & Marketing Director, CETA in BA East (2025–2026). The profile cites more than 15 years in pharmacy and physician-driven markets.

Experience: Global Brand Lead, Ozempic · Novo Nordisk

Global Brand Lead, Ozempic at Novo Nordisk (2020–2021) and Global Brand Lead, Rybelsus (2021–2023), after Product Manager, Ozempic (2018–2020); Oren has been Global Commercial Associate Director at Novo Nordisk since 2023. The profile headline lists brand and commercial strategy, go-to-market and launch work in diabetes, CVD and CKD.

Experience: Executive Director, Zepbound Commercial Strategy · Eli Lilly and Company

Former Executive Director, Zepbound Commercial Strategy at Eli Lilly and Company (2022–2026), after Senior Director, HCP Marketing - US GLP-1 Diabetes (2021–2022) and Global Brand Director, Pre-launch, Diabetes (2018–2019) at Lilly. Silvia has been Head of US Marketing at Zealand Pharma since July 2026, and the profile describes 13+ years at Eli Lilly building and launching brands and expertise in launch execution in the cardio-metabolic space.

Experience: Associate Director - Mounjaro Obesity Marketing, Saudi Arabia, Bahrain, and Oman · Eli Lilly and Company

Associate Director - Mounjaro Obesity Marketing, Saudi Arabia, Bahrain, and Oman at Eli Lilly and Company since December 2024, after Group Marketing Lead - Mounjaro Diabetes at the Saudi Arabia regional headquarters (2024) and Mounjaro Group Brand Manager - Launch Lead (2022–2023). Yossr's profile headline describes a GLP-1 and cardiometabolic launch leader across GCC markets, following marketing roles at Sanofi (2019–2022).